⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689177 | 1.00 | — | — | |
| SCHEMBL690902 | 1.00 | — | — | |
| SCHEMBL690715 | 0.86 | PIM1 (0.36) | — | |
| SCHEMBL689055 | 0.84 | L3MBTL3 (0.41) | — | |
| SCHEMBL689955 | 0.75 | NSD2 (0.32) | — | |
| SCHEMBL689195 | 0.75 | — | — | |
| SCHEMBL3647817 | 0.74 | L3MBTL3 (0.36) | — | |
| SCHEMBL172592 | 0.72 | — | — | |
| SCHEMBL81996 | 0.72 | — | — | |
| SCHEMBL172541 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | claimed |
| CN-113454086-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-107652289-B | Substituted tricyclic compounds as FGFR inhibitors | 因塞特控股公司 | 2020-07-21 | — | — | CN | claimed |
| US-10556908-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-02-11 | — | — | US | claimed |
| US-20190106426-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-04-11 | — | — | US | claimed |
| EP-3176170-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2018-11-14 | — | — | EP | claimed |
| US-10112950-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-10-30 | — | — | US | claimed |
| US-20170369497-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | claimed |
| US-9695180-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | claimed |
| WO-2016007736-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | claimed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| WO-2005021533-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2005-03-10 | — | — | WO | claimed |
| WO-2005021532-A1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054670-A1 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. | 2005-03-10 | — | — | US | claimed |
| US-20050049253-A1 | Substituted quinolinone derivatives and methods of use | AMGEN INC. | 2005-03-03 | — | — | US | claimed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | claimed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | claimed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | claimed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |